AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Neuronyx inc anne schoemaker3/5/2023 ![]() in finance from The Wharton School of the University of Pennsylvania. ![]() in economics from Dartmouth College and an M.B.A. Webster has served as a director of Nabriva Therapeutics plc, a publicly traded biopharmaceutical company, since August 2016 and Viking Therapeutics, Inc., a publicly traded biopharmaceutical company, since May 2014. Leslie Russell, Anne Faulkner Schoemaker, and Dr. Webster previously served in positions of increased responsibility, including as Director, Investment Banking Division, Health Care Group for PaineWebber Incorporated. Neuro Synchrony Clinics specializes in the evaluation and treatment of adults with neurologic disorders, memory disorders, fatigue, and sleep disorders. SCIENTIST, COMMUNITY LEADER AND FOUNDER OF CENTOCOR AND NEURONYX. Webster served as co-founder, President and Chief Executive Officer for Neuronyx, Inc., a biopharmaceutical company, from 2000 to 2006. Webster served as Managing Director, Investment Banking Division, Health Care Group for Broadpoint Capital Inc. From 2007 until joining Adolor Corporation in 2008, Mr. Webster served as SVP and Chief Financial Officer of Adolor Corporation, a biopharmaceutical company, from 2008 until its acquisition by Cubist Pharmaceuticals, Inc. Genzyme the Laguna A founding partner of Bay City Hubert Schoemaker co-founded Helmut. Maureen, Katherine, Anne, and Hubert Matthew Schoemaker) (en). Initial work focused on using stem cells taken from adult bone. In 1973 substantial contributions to the & Company, a South San an. In 1999 he founded Neuronyx, Inc., for the manufacture of stem cells and the development. ![]() in October 2013. Prior to joining Optimer, Mr. After Schoemaker died in 2006 the company was continued by his wife Anne Faulkner Schoemaker. Faulkner Schoemaker, a major Neuronyx shareholder, joined the companys board following her husbands death a year ago. ![]() He was previously Senior Vice President and Chief Financial Officer of Optimer Pharmaceuticals, Inc., a publicly traded biotechnology company, from July 2012 until its acquisition by Cubist Pharmaceuticals, Inc. Webster has served as the Chief Financial Officer of Spark Therapeutics, Inc., a publicly traded biotechnology company, since July 2014. Webster has served as a member of our board of directors since April 2019. ![]()
0 Comments
Read More
Leave a Reply. |